Testing a new medication for a rare immune disorder with skin and lupus symptoms

Plain-English translation of NCT07262983 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

What is this trial?

This pilot study is testing a medication called to see if it is safe and well-tolerated in people with Job syndrome—a rare immune disorder—who also experience lupus-like symptoms and/or severe atopic dermatitis (eczema). Researchers will monitor participants closely for about 6 months to understand how the medication affects their condition, infections, skin symptoms, and overall quality of life.

Job syndrome is a rare genetic immune disorder, and some people with this condition develop lupus-like symptoms or severe eczema that can be difficult to manage. This medication may help address both the immune system problems and the skin symptoms, but researchers need to first confirm it is safe in this patient population.

Do you qualify?

You likely qualify if…

you are at least 12 years old
you have been diagnosed with Job syndrome caused by a STAT3 gene mutation
you meet criteria for lupus-like disease and/or have moderate-to-severe eczema
you are enrolled in the related NIH natural history study for this condition
you can take oral medication reliably and commit to following the study plan
you are willing to use effective contraception if you can become pregnant

You likely don't qualify if…

you have had a severe allergic reaction to baricitinib or similar JAK inhibitor medications
you are currently taking certain immunosuppressive medications or have taken them recently
you have taken rituximab (a monoclonal antibody) within the past 6 months
you are enrolled in another clinical trial testing an investigational drug
you are taking systemic steroid doses greater than 10 mg of prednisone equivalent per day

What participation looks like

You will begin with a 3-month screening phase where you track your infections and eczema to ensure your disease is stable before starting treatment. If you qualify, you will then take the medication by mouth for 180 days (about 6 months) while visiting the clinic for regular check-ups and blood work. Researchers will closely monitor you for any side effects, changes in infections, improvements in your skin symptoms, and how the treatment affects your quality of life.

Testing a new medication for a rare immune disorder with skin and lupus symptoms

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)